The research of efficacious non-invasive therapies for the treatment of brain diseases represents a huge challenge, as people affected by disorders of the central nervous system (CNS) will significantly increase. Moreover, the blood-brain barrier is a key factor in hampering a number of effective drugs to reach the CNS. This review is therefore focusing on possible interventions of nanomedicine-based approaches in selected diseases affecting the CNS. A wide overview of the most outstanding results on preclinical evaluations of the potential of nanomedicine in brain diseases (i.e. brain tumor, Alzheimer, Parkinson, epilepsy and others) is given, with highlights on the data with relevant interest and real possibility in translation from bench-to-bedside. Moreover, a critical evaluation on the rationale in planning nanosystems to target specific brain pathologies is described, opening the path to a more structured and pathology-tailored design of nanocarriers.
Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain / Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni. - In: CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS. - ISSN 1996-3181. - STAMPA. - 15:9(2016), pp. 1079-1091. [10.2174/1871527315666160915112210]
Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
RUOZI, Barbara;BELLETTI, Daniela;PEDERZOLI, FRANCESCA;FORNI, Flavio;VANDELLI, Maria Angela;TOSI, Giovanni
2016
Abstract
The research of efficacious non-invasive therapies for the treatment of brain diseases represents a huge challenge, as people affected by disorders of the central nervous system (CNS) will significantly increase. Moreover, the blood-brain barrier is a key factor in hampering a number of effective drugs to reach the CNS. This review is therefore focusing on possible interventions of nanomedicine-based approaches in selected diseases affecting the CNS. A wide overview of the most outstanding results on preclinical evaluations of the potential of nanomedicine in brain diseases (i.e. brain tumor, Alzheimer, Parkinson, epilepsy and others) is given, with highlights on the data with relevant interest and real possibility in translation from bench-to-bedside. Moreover, a critical evaluation on the rationale in planning nanosystems to target specific brain pathologies is described, opening the path to a more structured and pathology-tailored design of nanocarriers.File | Dimensione | Formato | |
---|---|---|---|
Giovanni Tosi-CNS&ND-MS.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
1.56 MB
Formato
Adobe PDF
|
1.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
cnsnddt-RUOZI et al. 2016.pdf
Open Access dal 02/09/2017
Tipologia:
AAM - Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione
3.17 MB
Formato
Adobe PDF
|
3.17 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris